Discusses a case study presented before a local institutional review board to review a protocol for a randomized, double-blind, placebo-controlled trial for the treatment of schizophrenia. Criteria for the eligibility of individuals to participate in the study; Evaluation of responses to standard available treatments for schizophrenia; Justification of the use of placebos.